A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Hepatocellular Carcinoma (HCC)
- Second Line Treatment
Interventions
- PROCEDURE: HAI-FOLFOX + bevacizumab + QL1706
- PROCEDURE: TACE + bevacizumab + TAS-102 + QL1706
Sponsor
Sun Yat-sen University
Collaborators